Sanofi-Aventis completes acquisition of Russian insulin plant
This article was originally published in Scrip
Executive Summary
A government commission overseeing foreign investments in Russia has approved Sanofi-Aventis's acquisition of a controlling stake in the Bioton-Vostok insulin plant in Orel, 360km south of Moscow. It becomes the company's first production facility in Russia.